Merit Medical Systems, Inc. (MMSI) is a leading global manufacturer and distributor of disposable medical devices used in interventional, diagnostic, and therapeutic medical procedures, primarily in the fields of cardiology, radiology, and endoscopy. The company was established in 1957 and has its headquarters in South Jordan, Utah.
MMSI offers a comprehensive portfolio of high-performance products for different medical fields. These products include inflation devices, catheter guide wires, microcatheters, drainage catheters, embolotherapy products, angioplasty balloons, stent delivery systems, and more. MMSI's products are designed to provide physicians with precise and effective tools to treat a wide array of medical conditions.
The company operates through two business segments: Cardiovascular and Endoscopy. The cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial disease, peripheral vascular disease, and other cardiovascular-related diseases. The endoscopy segment offers various devices for diagnosing and treating gastrointestinal conditions, pulmonary conditions, and other diseases.
As a globally reputed medical devices provider, MMSI serves hospitals, clinics, and medical facilities in over 60 countries worldwide. Firmly established in the US, the company has expanded its marketing network into several continental regions, including Europe, Asia, the Middle East, and Africa. MMSI also maintains several manufacturing facilities overseas, which helps cater to the ever-growing demand and meet international quality standards effectively.
MMSI continually invests in developing innovative and advanced products. The company's focus on research and development has resulted in a rich line of patented technologies, which has subsequently led to enhanced product offerings. This ability to design, engineer, and manufacture complex devices sets MMSI apart from many of its industrial peers.
Despite the highly competitive industry environment, MMSI has managed to maintain steady growth. This can partly be attributed to its effective customer-focused strategies and its commitment to delivering high-quality, cutting-edge medical devices. MMSI's strong financial performance reflects its resilience and adaptability in changing market conditions.
In a nutshell, Merit Medical Systems, Inc. continues to build upon its strong foundation and leadership in the medical device industry. With its consistent focus on innovation, its wide range of product offerings, and its dedication to superior quality, MMSI is well-positioned for long-term success.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Merit Medical Systems (NASDAQ: MMSI) reported strong third-quarter results, surpassing analyst estimates for both earnings and sales. Following this upbeat performance, the company raised its FY2026 adjusted EPS guidance and narrowed its sales guidance. Consequently, BTIG and Needham analysts maintained their "Buy" ratings and increased their price targets for MMSI stock.
Merit Medical Systems reported strong Q3 2026 results with total revenue up 8% year-over-year to $416 million and non-GAAP EPS increasing 22%. The company updated its 2026 guidance, expecting GAAP net revenue growth of 7.9% to 8.4% and a non-GAAP EPS range of $4.33 to $4.37. Merit Medical also announced the acquisition of SoloPACE for approximately $45 million, enhancing its Cardiac Therapies platform with temporary pacing technology for TAVR procedures.
Merit Medical (MMSI) reported Q3 2026 earnings of $1.12 per share, surpassing the Zacks Consensus Estimate of $1.04, and revenues of $416.24 million, exceeding the estimate by 1.43%. The company has consistently beaten EPS and revenue estimates over the last four quarters. Despite outperforming expectations, the stock holds a Zacks Rank #3 (Hold) due to mixed estimate revision trends, suggesting it will perform in line with the market.